Radiopharm Theranostics Limited Sponsored ADR (RADX) Price & Analysis

Compare

50 Followers

RADX Stock Chart & Stats

$4.82

-$0.80(-17.20%)

At close: Jan 08 4:00 PM EST

$4.82

-$0.80(-17.20%)

Day’s Range― - ―

52-Week Range$3.50 - $16.25

Previous CloseN/A

Volume12.21K

Average Volume (3M)44.86K

Market Cap

$52.60M

Enterprise Value$19.79M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Sep 24, 2026

EPS Estimate

-1.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.10

Shares Outstanding11,814,054

10 Day Avg. Volume35,230

30 Day Avg. Volume44,860

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)1.09

Price to Sales (P/S)13.46

P/FCF Ratio-1.33

Enterprise Value/Market Cap0.38

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$20.33

Price Target Upside321.78% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-3.21

Revenue Forecast (FY)$581.03K

Bulls Say, Bears Say

Bulls Say

Diagnostic AccuracyInterim data showing 92% concordance between RAD101 PET and MRI and detection of very small lesions indicates strong diagnostic sensitivity and potential to distinguish necrosis from active tumor.

Regulatory And Clinical ProgressionPositive Phase IIb imaging results supporting RAD101 would enable a registrational Phase III study and create a clear pathway toward regulatory validation.

Therapeutic DevelopmentSafety reviews that supported escalation to a higher therapeutic dose, alongside early tumor uptake with good tolerability, support advancement of the therapeutic radiopharmaceutical program.

Bears Say

Cash Runway ConstraintsLimited cash resources could constrain development programs unless additional partnerships or financing are secured.

Financing And Dilution RiskNeed for additional financing may require equity raises that could dilute existing shareholders and negatively affect the stock if funding terms are unfavorable.

Program And Timeline RiskInsufficient funding could delay clinical trial timelines and planned regulatory interactions, slowing progress toward commercialization milestones.

Radiopharm Theranostics Limited Sponsored ADR News

Radiopharm doses first patient in Phase 1/2a study of BetaBart

Radiopharm (RADX) Theranostics announced the dosing of the first patient in its First-In-Human, FIH, Phase 1/2a clinical trial...

9d ago

RADX

Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart

Radiopharm Theranostics Limited Sponsored ADR ( ($RADX) ) has shared an announcement. On 24 February 2026 Radiopharm Theranostics...

9d ago

RADX

Radiopharm reports cash balance of $34.52M as of December 31

Net cash outflows from operating activities for the 6 months ended December 31, 2025 totaled $22.67M. “2025 was...

1M ago

RADX

Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic

Radiopharm Theranostics Limited Sponsored ADR ( ($RADX) ) just unveiled an announcement. On 12 January 2026, Radiopharm Theranostics...

2M ago

RADX

Radiopharm increases ownership in Radiopharm Ventures to 87.5%

Radiopharm (RADX) Theranostics has increased its ownership stake in Radiopharm Ventures, a joint venture created with The University...

2M ago

RADX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

AIM

RADX

Radiopharm price target raised to $15 from $12 at Maxim

Maxim analyst Michael Okunewitch raised the firm’s price target on Radiopharm (RADX) to $15 from $12 and keeps...

3M ago

RADX

Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the price...

3M ago

RADX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

RADX

Radiopharm price target raised to $16 from $13 at B. Riley

B. Riley raised the firm’s price target on Radiopharm (RADX) to $16 from $13 and keeps a Buy...

3M ago

RADX

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Government actions, new deals, and other news bring up the top stock market stories on Monday. ...

3M ago

AMD

GOOG

Why Is Radiopharm Theranostics Stock (RADX) Up Today?

Radiopharm Theranostics stock soared on Monday after the company posted results from a clinical trial. ...

3M ago

RADX

Radiopharm achieves primary endpoint in 92% of patients in RAD 101 trial

Radiopharm (RADX) Theranostics announced interim data from the first twelve patients in its U.S. Phase 2b clinical imaging...

3M ago

RADX

Radiopharm Theranostics Announces Successful General Meeting Resolutions

An announcement from Radiopharm Theranostics Limited Sponsored ADR ( ($RADX) ) is now available. On December 3, 2025,...

3M ago

RADX

RADX FAQ

What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?

Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.50 and its highest was $16.25 in the past 12 months.

What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?

Radiopharm Theranostics Limited Sponsored ADR’s market cap is $52.60M.

When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?

Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 24, 2026 which is in 203 days.

How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?

Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 26, 2026. The company reported -$2.096 earnings per share for the quarter, the consensus estimate of -$2.096 by $0.

Is Radiopharm Theranostics Limited Sponsored ADR overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?

Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.

What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?

Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.23.

How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?

Radiopharm Theranostics Limited Sponsored ADR has 11,814,054 shares outstanding.

What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?

Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$2.096 in its last earnings report, expectations of -$2.096. Following the earnings report the stock price went down -2.353%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?

Currently, no hedge funds are holding shares in RADX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-86.18%

Trailing 12-Months

Asset Growth

6.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited Sponsored ADR

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited Sponsored ADR (RADX) Earnings & Revenues

Historic Earnings Reports

RADX Stock 12 Month Forecast

Average Price Target

$20.33

▲(321.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,7.126153846153846,9.032307692307693,10.938461538461539,12.844615384615384,14.75076923076923,16.65692307692308,18.563076923076924,20.46923076923077,22.375384615384615,24.28153846153846,26.18769230769231,28.093846153846155,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,6.382307692307692,7.544615384615384,8.706923076923076,9.869230769230768,11.03153846153846,12.193846153846152,13.356153846153845,14.518461538461537,15.68076923076923,16.84307692307692,18.005384615384614,19.167692307692306,{"y":20.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,5.972307692307692,6.724615384615385,7.476923076923077,8.22923076923077,8.981538461538461,9.733846153846155,10.486153846153847,11.23846153846154,11.990769230769232,12.743076923076924,13.495384615384616,14.247692307692308,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.16,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.61,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.49,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.64,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >